October 4, 2023
2 minute read
Jones TH, et al. Summary 704. Presentation location: European Society of Diabetes Annual Meeting. October 2-6, 2023. Hamburg, Germany (hybrid conference).
Disclosure: Jones reports receiving grants from the British Association of Clinical Diabetes Specialists.
- Men with type 2 diabetes and hypogonadism receiving testosterone therapy had reduced HbA1c at 3 months, 1 year, and 2 years.
- More data are needed to evaluate the cardiometabolic effects of testosterone therapy.
Testosterone therapy may lower HbA1c in men with type 2 diabetes and hypogonadism, according to presenters at the European Society of Diabetes Annual Meeting.
In an analysis of real-world data from an ongoing clinical audit, men who received testosterone therapy had reduced HbA1c at 3, 12, and 24 months compared to baseline.
“This study thus far confirms that testosterone supplementation has an effect on HbA1c over time.” Dr. T. Hugh Jones, Consultant Physician and Endocrinologist at Barnsley Hospital, Emeritus Professor of Andrology at the University of Sheffield, and Honorary Consultant Endocrinologist at the Royal Hallamshire Hospital in Sheffield, UK, spoke to Helio. “This audit supports the use of testosterone supplementation in hypogonadal men with type 2 diabetes. It is clear that the longer the follow-up period, the more data will be available and the more patients will be audited. is.”
The data presented by Jones et al. are the initial results of a multi-center audit being conducted by the British Association of Clinical Diabetes Specialists to assess the clinical effectiveness and monitoring of testosterone therapy in men with type 2 diabetes and hypogonadism. It is an analysis. Prospective and retrospective data from routine clinical practice were provided by 34 centers in 8 countries. HbA1c was assessed at baseline and after 3, 12, and 24 months. Of the study participants, 193 were on metformin, 99 on insulin, five on GLP-1 receptor agonists, and one on SGLT1 inhibitors.
There was a paired cohort of 80 men who were evaluated after 3 months. In this group, HbA1c decreased from 8.7% at baseline to 8.2% after 3 months (P < .001). Of the 121 cohort evaluated after 12 months, HbA1c decreased from 8.7% at baseline to 7.8% at follow-up (P < .001). Among the cohort of 104 pairs evaluated at 24 months, HbA1c decreased from 8.7% at baseline to 7.3% at 24 months (P < .001).
“Testosterone has a variety of effects on glucose and fat metabolism,” Jones says. “While some effects become apparent within a few weeks, the effects of reduced fat mass and increased muscle mass can last for months to years. Registry studies have reported this effect. ”
Jones said the audit data is important in analyzing the effects of testosterone therapy on type 2 diabetes, as long-term randomized controlled trials are unlikely to be conducted due to length and cost. He said the evidence for the effectiveness of testosterone therapy will become stronger as more facilities participate in the audit and more data becomes available.
“It’s important to recognize that this is early data,” Jones said. “We want to promote this audit to encourage new doctors in the specialty of treating testosterone deficiency in type 2 diabetes.”